Il pericolo ancora sottovalutato delle interazioni tra farmaci. Un caso clinico esemplificativo

Autori

  • Giovanni Polimeni Specialista in Farmacologia, Università di Messina
  • Maria Antonietta Catania Specialista in Tossicologia Medica, Università di Messina

DOI:

https://doi.org/10.7175/pmeal.v1i3.423

Parole chiave:

Statin, Interaction risk, Rhabdomyolysis

Abstract

Treatment of hypercholesterolemia has been shown to reduce mortality in patients with coronary artery disease. Patients with severe lipid abnormalities may require high-dose statin therapy, at times used in combination with additional agents. The occurrence of rhabdomyolysis is one of the rare side-effects of the cholesterol-lowering agents. During the use of simvastatin, the risk of this side-effect might be increased when macrolides are used concomitantly. The interacting mechanism likely was inhibited cytochrome P450 (CYP) 3A4 metabolism and possibly P-glycoprotein transport of simvastatin as well. We present a patient who developed rhabdomyolysis during the concomitant use of simvastatin and erythromycin. Coprescribing of medications not compatible with statins occurs frequently: to prevent future events, it is crucial that clinicians recognize the interaction risk associated with coprescribing, to assure that the risk of untoward effects is mitigated.

##submission.downloads##

Pubblicato

2007-08-15

Fascicolo

Sezione

Articolo